TrialThe journal of prevention of Alzheimer's disease2026

Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease.

Claude M Wischik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.